<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652730</url>
  </required_header>
  <id_info>
    <org_study_id>980564</org_study_id>
    <nct_id>NCT00652730</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions</brief_title>
  <official_title>Comparative, Randomized, 3-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar)15 mg Buspirone HCl Tablets Following Administration of a 30 mg Dose in Healthy Adult Males Under Fed and Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Phoenix International Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl
      Tablets
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the single-dose bioavailability of Par and Bristol-Myers Squibb (Buspar) 15 mg
      buspirone HCl tablets, following administration of a 30 mg dose, under fed conditions. In
      addition, the bioavailability of the Par product was compared under fed and fasting
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">September 1998</completion_date>
  <primary_completion_date type="Actual">September 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>To Determine Bioequivalence Under Fed Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the Par formulated product under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the Par formulated product under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the Bristol-Myers Squibb formulated product under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone HCl</intervention_name>
    <description>Tablets, 30 mg, single-dose, fasting conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Buspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone HCl</intervention_name>
    <description>Tablets, 30 mg, single-dose, fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Buspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspar</intervention_name>
    <description>Tablets, 30 mg, single-dose, fed conditions</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Buspirone HCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers, 18-45 years of age

          -  Weighing at least 60 kg, who are within 10% of their ideal weights (Table of
             &quot;Desirable Weights of Adults&quot;, metropolitan Life Insurance Company, 1983)

          -  Physical examination and laboratory tests of hematologic, hepatic and renal functions.

          -  Medically healthy subjects with clinically normal laboratory profiles will be enrolled
             in the study

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or
             psychiatric disease.

          -  In addition, the presence of alcoholism or drug abuse within the past year:
             hypersensitivity or idiosyncratic reaction to buspirone HCl.

          -  Subjects who have been receiving monoamine oxidase inhibitors.

          -  Subjects who have been on an abnormal diet (for whatever reason) during the 28 days
             preceding the study.

          -  Subjects who, through completion of the study, would have donated in excess of 500 mL
             blood in 14 days, or 500-750 mL blood in 14 days (unless approved by the Principal
             Investigator, 1000 mL blood in 90 days, 1250 mL blood in 120 days, 1500 mL blood in
             180 days, 2000 mL blood in 270 days, 2500 mL blood in 1 year.

          -  Subjects who have participated in another clinical trial with 28 days of study start.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Surfaty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix International Life Sciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix International Life Sciences inc</name>
      <address>
        <city>St-Laurent</city>
        <state>Quebec</state>
        <zip>H4R 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin/Director of Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc</organization>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>buspirone HCl</keyword>
  <keyword>fed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

